CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a fourth-quarter loss of $22.8 million, after reporting a profit in the same period a year earlier.
The Cambridge, Massachusetts-based company said it had a loss of 10 cents per share.
The kidney disease treatment developer posted revenue of $46.5 million in the period.
For the year, the company reported that its loss widened to $69.4 million, or 33 cents per share. Revenue was reported as $160.2 million.
The company's shares closed at $1.93. A year ago, they were trading at $1.42.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AKBA at https://www.zacks.com/ap/AKBA
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。